Abstract
The treatment of stage I non-seminomatous germ cell (NSGCT) tumor includes retroperitoneal lymph node dissection (RPLND) for patients with high-risk tumor characteristics and for those patients with residual masses after primary chemotherapy. Laparoscopic RPLND (L-RPLND) was initially performed to reduce the morbidity associated with open RPLND (O-RPLND) and at the same time maintain the staging and therapeutic benefits of lymph node removal. However, L-RPLND is a challenging procedure and requires extensive experience with laparoscopic techniques including laparoscopic control of bleeding. Robotic RPLND (R-RPLND) provides enhanced endoscopic visibility, improved dexterity, and superior control of bleeding over L-RPLND. The robotic platform has allowed for a full bilateral RPLND to be performed in one setting without the need to reposition the patient. The bilateral approach as well as improved vascular control has permitted R-RPLND to be expanded to patients with post chemotherapy masses.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
